BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization
false
áéåìééï àø à÷ñ áò"î
2
380
BIOLINE RX LTD
Corporation no:
513398750
8688
Israel Securities Authority
Tel Aviv Stock Exchange
C002
(
Public
)
Reported via MAGNA:
10/11/2022
www.isa.gov.il
www.tase.co.il
Reference:
2022-02-108789
Time of broadcast:
13:41
13:41
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization
FORM_6-K_10-Nov-2022_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
NASDAQ CM
Date of revision of form structure:
02/11/2022
Address:
HaMa'ayan
2
,
Modi'in
7177871
,
Israel
Tel:
08-6429100
,
Fax:
08-6429101
E-mail address:
info@BioLineRx.com
Company site:
www.biolinerx.com
Previous names of reporting entity:
Name of the Signatory:
Serlin Philip Adam
Position of Signatory in the reporting corporation:
Chief Executive Officer
Name of Employer Company:
Address:
HaMa'ayan
2
,
Modi'in
7177871
Telephone:
08-6429100
Facsimile:
08-6429101
E-mail:
phils@biolinerx.com
1
Israel